Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Neuroregenerative and Neuroprotective Effects of Bioengineered Scaffolds in Spinal Cord Injury: A Systematic Review of Preclinical and Early Phase Clinical Studies Publisher



A Khavandegar ARMIN ; N Safari Dehnavi NEGIN ; M Ganau MARIO ; Z Ramezani ZAHRA ; E Khodadoust ELAHEH ; Ms Hassan Zadeh Tabatabaei Mahgol SADAT ; Te Maleki Tahereh EZAZI ; Ma Mousavi Maryam ALSADAT ; K Rayatsanati KIMIA ; M Esmaeili MAHSA
Authors

Source: Spinal Cord Published:2025


Abstract

Study design: Systematic Review Objectives: To systematically examine the use of bioengineered scaffolds, with/without bioactive agents, drugs, or cellular transplants in preclinical animal models and human studies of spinal cord injury (SCI). Setting: Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences Methods: A systematic review and meta-analysis was conducted following PRISMA guidelines and registered in PROSPERO (ID: CRD42023437266). A comprehensive search in MEDLINE and Embase on 8/27/2023 identified studies on scaffolds as neuroregenerative and neuroprotective treatments for SCI. Human studies were assessed using ROBINS-I, and meta-analysis focused on clinical outcomes. Results: Of 4561 articles screened, 931 studies were included: in-vivo (82%), in-vitro (16%), and human studies (1%). Various biomaterials (N = 82; natural: 38%; synthetic: 62%), cell types (N = 27; NSCs: 24%, Schwann cells: 13%, NPCs: 12%), bioactive agents (N = 38; NT-3: 32%, BDNF: 25%, FGF: 24%), and pharmacological agents (N = 88; chABC: 12%, heparin: 11%, taxels: 10%) were analyzed. Fourteen human studies included acute and chronic SCI patients, with cervical (36%) and thoracic SCI (64%). Clinical trials demonstrated moderate to low quality (ROBINS-I). Our meta-analysis indicated that the pooled 2-scale AIS conversion rate was 30.59% (p = 0.005) ranging from 33.46% (p = 0.036) in acute to 28.35% (p = 0.084) in chronic SCI. Furthermore, the pooled 1-scale AIS conversion rate was 11.79% (p = 0.011), spanning from 17.31% (p = 0.131) in acute to 7.44% (p = 0.081) in chronic SCI. Conclusion: Scaffold implantation shows promising neuroregenerative potential, evidenced by AIS grade improvement in human studies. Scaffolds are advancing rapidly from laboratory research to clinical trials, expanding treatment options for SCI. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. A Combination of Mesenchymal Stem Cells and Scaffolds Promotes Motor Functional Recovery in Spinal Cord Injury: A Systematic Review and Meta-Analysis, Journal of Neurosurgery: Spine (2020)
2. Timing of Decompressive Surgery in Patients With Acute Spinal Cord Injury: Systematic Review Update, Global Spine Journal (2024)
3. Inhibition of Phosphodiesterase Iv Enzyme Improves Locomotor and Sensory Complications of Spinal Cord Injury Via Altering Microglial Activity: Introduction of Roflumilast As an Alternative Therapy, International Immunopharmacology (2020)
Experts (# of related papers)
View all Related Experts
Vafa Rahimi-Movaghar (4)
Somayeh Ebrahimi Barough (2)
Other Related Docs
4. Hydrogel-Encapsulated Extracellular Vesicles for the Regeneration of Spinal Cord Injury, Frontiers in Neuroscience (2023)
5. Neurological Recovery and Neurogenesis by Curcumin Sustained-Release System Cross-Linked With an Acellular Spinal Cord Scaffold in Rat Spinal Cord Injury: Targeting Nlrp3 Inflammasome Pathway, Phytotherapy Research (2024)
6. Animal Models of Spinal Cord Injury: A Systematic Review, Spinal Cord (2017)
7. Tissue-Engineered Regeneration of Hemisected Spinal Cord Using Human Endometrial Stem Cells, Poly Ε-Caprolactone Scaffolds, and Crocin As a Neuroprotective Agent, Molecular Neurobiology (2017)
8. Evaluating the Anti-Neuropathic Effects of the Thymol-Loaded Nanofibrous Scaffold in a Rat Model of Spinal Cord Injury, Frontiers in Pharmacology (2025)
9. Reprogramming of Astrocytes to Neuronal-Like Cells in Spinal Cord Injury: A Systematic Review, Spinal Cord (2024)
10. Advanced Approaches to Regenerate Spinal Cord Injury: The Development of Cell and Tissue Engineering Therapy and Combinational Treatments, Biomedicine and Pharmacotherapy (2022)
11. Carbohydrates and Neurotrophic Factors: A Promising Partnership for Spinal Cord Injury Rehabilitation, Biomaterials Advances (2025)
12. The Effect of Collagen and Fibrin Hydrogels Encapsulated With Adipose Tissue Mesenchymal Stem Cell-Derived Exosomes for Treatment of Spinal Cord Injury in a Rat Model, Iranian Journal of Biotechnology (2023)
13. Therapeutic Potential of Placenta-Derived Stem Cells Cultivated on Noggin-Loaded Nanochitosan/Polypyrrole-Alginate Conductive Scaffold to Restore Spinal Cord Injury, Stem Cell Research and Therapy (2024)
14. Mechano-Transduction Signals Derived From Self-Assembling Peptide Nanofibers Containing Long Motif of Laminin Influence Neurogenesis in In-Vitro and In-Vivo, Molecular Neurobiology (2017)
15. Chimeric Self-Assembling Nanofiber Containing Bone Marrow Homing Peptide’S Motif Induces Motor Neuron Recovery in Animal Model of Chronic Spinal Cord Injury; an in Vitro and in Vivo Investigation, Molecular Neurobiology (2016)
16. Biomimetic Engineered Approaches for Neural Tissue Engineering: Spinal Cord Injury, Journal of Biomedical Materials Research - Part B Applied Biomaterials (2023)
17. Advances in Management of Spinal Cord Injury Using Stem Cell-Derived Extracellular Vesicles: A Review Study, Basic and Clinical Neuroscience (2023)
18. Stem Cell Therapy for Locomotion Recovery and Neuropathic Pain Alleviation in Spinal Cord Injury: An Umbrella Review and Meta-Analysis, Spinal Cord (2025)
19. Prevention, Diagnosis, and Management of Intraoperative Spinal Cord Injury in the Setting of Spine Surgery: A Proposed Care Pathway, Global Spine Journal (2024)
20. Placenta Mesenchymal Stem Cells Differentiation Toward Neuronal-Like Cells on Nanofibrous Scaffold, BioImpacts (2020)